RemeGen Co., Ltd. (HKG:9995)

Market Cap	55.53B +388.6%
Revenue (ttm)	2.43B +46.3%
Net Income	-1.04B
EPS	-1.91
Shares Out	556.51M
PE Ratio	n/a
Forward PE	112.81
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,442,330
Average Volume	4,981,562
Open	80.40
Previous Close	80.35
Day's Range	79.20 - 81.80
52-Week Range	12.72 - 126.60
Beta	0.68
RSI	39.11
Earnings Date	Mar 28, 2026

About RemeGen

RemeGen Co., Ltd., a biopharmaceutical company, discovers, develops, produces, and commercializes biological drugs for the treatment of autoimmune, oncology, and ophthalmic diseases in Mainland China and the United States. The company offers Telitacicept (RC18) for the treatment of systemic lupus erythematosus (SLE) autoimmune disease; and Disitamab Vedotin (RC48), an antibody drug conjugate for the treatment of various cancers. It also develops products in various stages, including RC-28E, a fusion protein that targets vascular endothelial gro...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2008
• Employees: 3,070
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 9995

Financial Performance

In 2024, RemeGen's revenue was 1.72 billion, an increase of 58.54% compared to the previous year's 1.08 billion. Losses were -1.47 billion, -2.84% less than in 2023.

Financial numbers in CNY